Hubei Goto BiopharmLtd Management
Management criteria checks 3/4
We currently do not have sufficient information about the CEO.
Key information
Zubin Xi
Chief executive officer
CN¥729.3k
Total compensation
| CEO salary percentage | n/a |
| CEO tenure | 6.2yrs |
| CEO ownership | 31.7% |
| Management average tenure | no data |
| Board average tenure | 4.7yrs |
Recent management updates
Recent updates
Hubei Goto Biopharm Co.,Ltd. (SZSE:300966) Shares Fly 42% But Investors Aren't Buying For Growth
Oct 09
Hubei Goto Biopharm Co.,Ltd. (SZSE:300966) Held Back By Insufficient Growth Even After Shares Climb 26%
May 12Hubei Goto BiopharmLtd's (SZSE:300966) Soft Earnings Are Actually Better Than They Appear
May 02Lacklustre Performance Is Driving Hubei Goto Biopharm Co.,Ltd.'s (SZSE:300966) Low P/S
Feb 28CEO
Zubin Xi (54 yo)
6.2yrs
Tenure
CN¥729,300
Compensation
Mr. Zubin Xi is Chairman of the Board of Hubei Goto Biopharm Co.,Ltd. and serves as General Manager. He serves as Research and development Director at Hubei Goto Biopharm Co.,Ltd.since October 2021. He wa...
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Chairman of the Board | 6.2yrs | CN¥729.30k | 31.72% CN¥ 606.3m | |
| CFO & Non-Independent Director | 6.2yrs | CN¥361.60k | no data | |
| Non Independent Director & Deputy GM | 6.2yrs | CN¥606.40k | 11.91% CN¥ 227.6m | |
| Non Independent Director | 3.2yrs | CN¥244.00k | no data | |
| Chairman of the Supervisory Board | 6.2yrs | no data | 1.04% CN¥ 19.8m | |
| Non-Employee Supervisor | 6.2yrs | no data | no data | |
| Independent Director | less than a year | no data | no data | |
| Non-employee supervisor | less than a year | no data | no data | |
| Independent Director | less than a year | no data | no data | |
| Independent Director | less than a year | no data | no data |
4.7yrs
Average Tenure
53.5yo
Average Age
Experienced Board: 300966's board of directors are considered experienced (4.7 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/25 09:45 |
| End of Day Share Price | 2024/12/25 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Hubei Goto Biopharm Co.,Ltd. is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|